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ABSTRACT
Keloid occurs due to hyperactivity of keloid fibroblast (KF) in proliferation, migration, 
collagen deposition, together with low rates of collagen degradation. These are under 
the responsibility of TGF-b. Mitomycin C (MC) is used for treating keloid by a topical 
application during surgery at the level of 0.02% to 0.08%. Unfortunately, the lowest 
effective level of MC for keloid has not been determined yet. We aimed to determine 
the lowest effective level of MC in the suppression of KF activities. Various levels of MC 
diluted in growth medium were administered on KF that were isolated from six patients. 
After 24 hours and 72 hours of incubation, cellular proliferation, collagen deposition, 
cellular migration and level of TGF-b, were analyzed. Application of 120 uM MC on KF 
culture for 24 hours could significantly reduce TGF-b production from 1265.74 ± 274.81 
pg/mL to 265.17 ± 12.20 pg/mL; proliferation index from 100% to 84.01 ± 12.91%; 
inhibit cellular migration to 64.38 ± 3.66%; but reduce collagen depositions from 100% 
to only 91.13 ± 10.19%. The lowest MC level is on 30 uM or equal with 0.001%. 
In conclusion, the lowest level of MC can suppress the activities of KF is 0.001%. 
Moreover, due to low activity in inhibiting collagen deposition, MC would be better as an 
adjuvant drug for keloid surgery.
ABSTRAK
Keloid timbul karena proliferasi, migrasi, dan sintesis kolagen oleh fibroblas keloid 
(FK) secara berlebihan diikuti dengan rendahnya degradasi kolagen. Semua itu terjadi 
karena pacuan TGF-b. Olesan mitomycin C (MC) 0,02% sampai 0,08% digunakan untuk 
mengobati dan mencegah kekambuhan keloid yang dioperasi. Sayangnya, dosis terendah 
yang masih efektif belum pernah diteliti. Penelitian ini bertujuan untuk menentukan 
kadar terendah MC yang masih efektif untuk mengobati keloid. MC dilarutkan dalam 
medium pertumbuhan dalam berbagai kadar dan diberikan pada biakan FK yang diisolasi 
dari material keloid enam orang pasien. Setelah inkubasi 24 jam dan 72 jam, proliferasi, 
migrasi, timbunan kolagen dan kadar TGF-b, dianalisis dan dibandingkan. Pemberian 120 
uM MC pada biakan FK ternyata dapat menurunkan produksi TGF-b dari 1265,74 ± 
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274,81 pg/mL menjadi 265.17 ± 12.20 pg/mL; indek proliferasi dari 100% menjadi 
84,01 ± 12.91%; menghambat migrasi sampai 64,38 ± 3.66%, tetapi daya hambat 
timbunan kolagen hanya dari 100% menjadi 91.13 ± 10.19%. Kadar MC terendah yang 
masih efektif adalah 30 uM atau setara dengan 0.001%. Kadar MC di bawah itu tidak lagi 
efektif. Kesimpulan, kadar MC terendah yang masih efektif sebesar 0,001% dan karena 
daya hambat timbunan kolagen yang rendah, MC sebaiknya digabung dengan operasi 
keloid. 
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INTRODUCTION
Keloid is a fibroproliferative benign 
tumor that found only on human skin with 
characteristics in persistent overgrowth of 
fibrous tissues during wound healing leading 
to the formation of over scar tissues more 
than original wound size, and can invade 
surrounding normal tissue as a crab-claw 
of keloid lesion.1,2 This overgrowing is due 
to keloid fibroblast (KF) proliferation and 
producing collagen excessively3-5 together 
with low activity of extracellular matrix 
metalloproteinase (MMP).6,7 KF also have a 
characteristic of mesenchymal stem cells and 
can migrate to surrounding normal tissues 
to produce enlargement of fibrous tissues.8 
Moreover, one of various growth factors that 
have an important role in keloid behavior 
is transforming growth factor-β (TGF-β).9 
This growth factor can induce Wnt/β-catenin 
signaling,10 and over-expression of Wnt is 
parallel with collagen deposition in both keloid 
tissues and KF culture.11,12 Wnt/β catenin 
signaling pathway is not only responsible 
for collagen production but it also has an 
important role in inducing transformation of 
human dermal microvascular endothelial cells 
to become KF.12
Mitomycin-C (MC) is an anti-cancer 
commonly used for bladder cancer and 
others, including as the preventing agent 
for pterygium by topical application intra-
operatively.13 Interestingly, the target of 
this agent is pterygial body fibroblasts that 
produce fibrotic tissues under stimulation 
of connective tissue growth factor (CTGF) 
initiated by TGF-β.14 Similar with it, MC 
is also used in keloid lesion by topical 
application intra-operatively to suppress 
KF activities. Talmi et al15 apply MC to the 
wound of keloid excision and resulting in 
the complete disappearance of keloid lesion. 
MC can prevent keloid recurrence up to 80% 
when applied topically to the base of shave-
removing keloid surgery.16 The side effects 
of topical application of 0.02% MC (equal 
with 598 uM) among patients with pterygium 
is low, mild, and reversible.13 Application of 
MC intra-operatively is ranged from 0.02% 
to 0.08% (equal with 2393 uM), but whether 
0.02% as the lowest effective level of MS is 
still unknown. In order to know the lowest 
level of MC in topical-application for keloid 
surgery, we reported the effect of various 
low level MC on KF culture, therefore, the 
best level of MC in keloid surgery may be 
determined.
MATERIAL AND METHODS
Isolation and culture of KF
The core of keloid materials was obtained 
from six patients underwent keloid debulking 
surgery with informed concerns. About 2 cm3 
of each material was thinly sliced into 2-3 
mm3 pieces and cultured by explants method 
in Dulbecco’s Modified Eagle’s Medium 
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(DMEM, Gibco®, USA) containing 10% 
fetal bovine serum (FBS, Gibco®,USA) and 
1% penicillin/streptomycin (Gibco®, USA) at 
37°C and 5 % CO2. The spindle-shaped cells 
that outgrown from the explants then were 
subcultured until passage 4.
Experiments
Stock MC-preparation
MC (molecular weight = 334.33) was 
purchased from Biochem Pharmaceutical 
Industry Ltd., Mumbai, India under license 
from Kyowa Hakko Kogyo, Japan. After 
dissolving 10 mg MC in 25 mL sterile water 
(molarity = 1.1964mM), further dilution with 
DMEM was performed until stock MC in the 
level of 600 uM. Referring to the findings of 
Wang et al.,17 on human dermal fibroblasts, 
we began to treat KF with 120 uM MC. 
Design and treatment
All of the experiments were then 
conducted in the following scheme: 
FIGURE 1. Preparation and measurement scheme
The experiment was carried out with KF 
reseeding in wells of 200 uL cell suspension 
containing 103 cells/mL. After 24 hours of 
incubation to let cells attached on the bottom 
of wells, various treatments carried out in 
accordance with a written scheme on above. 
All of the procedures were in triplicate.
Measurement of variables
Proliferation index
Cellular viabilities were measured using 
MTT {-(3-(4.5-dimethylthiazol-2-yl)-2.5-
diphenyltetrazolium bromide purchased from 
MP biomedical-France} assay and optical 
density (OD) of formazan blue produced 
by living cells and were determined using 
spectrometer at 570 nm of wavelength. 
All of the ODs from the control group was 
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considered as 100% of the proliferation index, 
therefore, the proliferation index of various 
treated groups was counted as: (OD of treated 
group / OD of paired control) x 100 %.
Ability to deposite collagen 
Collagen deposition was measured by 
insoluble collagen of Sirius red (purchased 
from Sigma-Aldrich, Steinheim, Germany) 
assay according to Taskiran et al.,18 the OD 
Sirius red-bound collagen represented the 
amount of insoluble collagen and it was read 
using spectrometer at 570 nm of wavelength. 
The OD of the control group was considered 
as 100%ability to deposit collagen.The ability 
of various treated groups was counted as: (OD 
of treated group / OD of paired control) × 100 
%.
Inhibition of cellular migration
Cellular migration assay was performed 
based on method Liang et al.,19 briefly, after 
serum starvation,all bottom of wells were 
linearly scratched with the blunt tip of a 32G 
sterile needle through the center of the well 
bottom. After cultivation with various media 
and incubations, the cells were then stained 
with Meyer’s Haematoxylin and microscopic 
photo images were taken using a Moticam-350 
camera (China) in JPG format. Both blue 
color’s pixels of fibroblasts along the scratch 
line and white color’s pixels of empty space 
can be measured using Adobe-Photoshop. 
Migration rate was counted as: (blue color 
pixel of KF along the scratch line / total pixel 
along the scratch line ) × 100%. Inhibition 
of migration of treated group was counted as 
migration rate of control minus migration rate 
of paired treated group.
TGF-β level
The level of TGF-β in the supernatant of 
various groups was measured using human 
TGF-β 1 ELISA kit purchased from Bender 
MedSystem (Burlingame, USA). The OD of 
each well was read using spectrometer at 570 
nm of wavelength and the level of TGF-βwas 
counted using standard curve obtained from 
a correlation between various standardized 
TGF-β with their OD. 
Statistics
All data are presented as a mean ± standard 
error. We used one -ay analysis of variance 
(ANOVA) followed by LSD to analyze the 
migration rate data and Friedman test followed 
by Wilcoxon as post hoc test to analyze the 
proliferation index and collagen deposition 
data. The level of statistical significance was 
accepted at p<0.05.
RESULTS 
Application of 120 uM MC on KF culture 
for 24 hours can reduce: TGF-β production 
from: 1265.74 ± 274.81 pg/mL to 265.17 
± 12.20 pg/mL; collagen depositions from 
100% to 91.13 ± 10.19%; proliferation index 
from 100% to 84.01 ± 12.91%; and inhibit 
cellular migration up to 64.38 ± 3.66%. The 
effect of diluted MC on KF culture both for 
24 hours and 72 hours can be observed in the 
following FIGURES.
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FIGURE 2. Effect of MC on proliferation and cellular migration
FIGURE 3. The effect of MC on TGF-β and collagen deposition
DISCUSSION
Various keloid treatments, starting from 
surgery to intralesional corticosteroid and 
various anti-cancers such as fluorouracil,20 
bleomycin,21 MC,15,16,22 or a combination of 
them have been performed.23 MC has been 
chosen because it can inhibit normal skin 
fibroblast proliferation, induce fibroblast 
apoptosis, and regulate intracellular protein 
expression on mRNA level.17
Our results showed that 120 uM MC 
can inhibit proliferation and migration of KF 
FIGURE 1. This finding is important because 
continuously enlargement of keloid lesion is 
under responsible of high proliferation rate 
of KF3-5 and high migration ability to invade 
surrounding normal tissue.8 Application 120 
uM MC for 72 hours had no significantly 
different effect in proliferation index and 
inhibition of cellular migration than 24 hours. 
Dilution of 120 uM MC into a quarter, one-
eighth and so on indicated that significant 
different (p < 0.05) in KF proliferation and 
migration was existed on 7.5 uM and below, 
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both 24 hours and 72 hours of administration. 
So, it can be concluded that lowest level of 
MC is on the level of 30 uM or equal to 10.03 
ug/mL or equal to 0.001%.
Regulation of KF protein expression by 
120 uM MC can be observed in FIGURE 2, 
as it was indicated by reducing the TGF-β 
level and collagen deposition. Based on low 
inhibition of collagen deposition (about 10% 
of 24 hours of incubation), it seemly indicated 
that MC as a single drug is not worthy to be used 
for treating keloid lesion otherwise  repeated 
injections of MC must be given. Based on high 
inhibition of MC in cellular migration and 
cellular proliferation on above, it looked that 
MC administration just has prevention effect 
in keloid progression. It has been known that 
extensive enlargement of keloid lesions is due 
to KF proliferations, collagen depositions, 
and cellular migrations.3-5 In order to totally 
treat keloid lesions, we agree that MC must be 
combined with keloid surgery that removes the 
existing fibrous tissue material which richens 
by collagen bundles, such as previously 
reported by many authors.15,16,22,23 In this 
combination, unremoving KF and collagen 
bundles on the surface of debulking lesions of 
preexisting keloid can be prevented to grow 
and to be prevented to relapse. The significant 
different of collagen deposition between 72 
hours and 24 hours of application (as it shown 
by red dot) showed that MC could stimulate 
collagen degradation as manifestation of 
MMP activation. Among KF, production of 
tissue inhibitor of metalloproteinase (TIMP)-
2 is high and MMP-2 is low. A study showed 
that application of IL-β can convert this 
event to become increasing MMP-2 level 
together with decreasing TIMP-2 parallel 
with increasing collagen degradation.24 We 
suspected that increasing collagen degradation 
in our experiment was due to MC regulate KF 
in interleukin-β protein expression. A further 
research to clarify this hypothesis should be 
performed in the future. 
So far, there is no any criterion for 
converting drug level obtained from cell 
culture to the equal dosage for human in 
clinical applications. Atashkina et al.25 
assume that so many variables must be 
considered before converting those drug’s 
levels in the human body, for example: 
whether cultured cellular models exhibiting 
reliable, known and intact biochemical 
pathways and structural elements are same 
with keloid lesions. For these purposes, our 
experiment in two dimensions KF culture 
had limitation at least in structural elements 
where excessive collagen bundles before 
having treatments were not represented in 
our cells condition. This limitation may 
affect on effective drug’s level that is lower 
than it should be in keloid lesion. Since there 
is no representative animal model for keloid 
study, a further study in three dimensions of 
organotypic keloid culture must be conducted, 
so the lowest effective level of MC can be 
determined. The comparison of 3 dimensions 
culture’s weight and the monolayer culture’s 
weight can be used to determine starting level 
of MC for further researches. 
CONCLUSION
MC is just applicable in preventing 
recurrence of keloid after having keloid 
surgery. Moreover, the lowest effective level 
of MC is 30 uM for a monolayer of KF culture 
or equal to 0.001% but it must be recalculated 
in the clinical application of keloid surgery 
and it depends on the estimation of residual 
fibrous tissues weight. 
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